MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Operating Expenses 2011-2026 | DBVT
Annual Operating Expenses DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121 M | 92.2 M | 101 M | 104 M | 135 M | 152 M | 166 M | 145 M | 116 M | 45.6 M | 39 M | 20 M | 13.6 M | 7.32 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 166 M | 7.32 M | 89.9 M |
Quarterly Operating Expenses DBV Technologies S.A.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.6 M | 27.4 M | 31.4 M | 35 M | 30 M | 20.6 M | 27.4 M | 23.4 M | - | 20.1 M | 25.4 M | 19.3 M | - | 25.7 M | 29.6 M | 32.6 M | - | 33.9 M | 51.3 M | 45.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.3 M | 19.3 M | 30.7 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
141 M | $ 18.24 | -1.41 % | $ 2.68 B | USA |
 |
Amgen
AMGN
|
9.33 B | $ 344.45 | 0.75 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 73.14 | 5.5 % | $ 9.78 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Biogen
BIIB
|
5.39 B | $ 178.43 | -0.81 % | $ 26 B | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.11 | -2.05 % | $ 7.48 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.77 | 0.83 % | $ 1.59 B | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
167 M | $ 1.39 | -1.42 % | $ 261 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 222.86 | -1.43 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.12 | 2.74 % | $ 8.96 B |  Israel |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 109.1 | -4.09 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.39 | 1.09 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
49.3 M | $ 1.75 | -0.29 % | $ 83.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Compugen Ltd.
CGEN
|
40.4 M | $ 1.85 | 0.54 % | $ 166 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.11 | 3.14 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
144 M | $ 6.64 | 0.91 % | $ 1.37 B | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
479 M | $ 27.95 | 1.19 % | $ 2.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |